Zacks Bull and Bear of the Day Highlights: Mueller, Cirrus Logic, Nektar Therapeutics, Novartis and Cubist Pharmaceuticals

   Zacks Bull and Bear of the Day Highlights: Mueller, Cirrus Logic, Nektar
              Therapeutics, Novartis and Cubist Pharmaceuticals

PR Newswire

CHICAGO, June 6, 2013

CHICAGO, June 6, 2013 /PRNewswire/ --Zacks Equity Research highlights Mueller
& Co (NYSE:MWA)as the Bull of the Day and Cirrus Logic, Inc. (Nasdaq:CRUS) as
the Bear of the Day. In addition, Zacks Equity Research provides analysis on
Nektar Therapeutics (Nasdaq:NKTR), Novartis (NYSE:NVS) and Cubist
Pharmaceuticals Inc. (Nasdaq:CBST).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Full analysis of all these stocks is available at
http://at.zacks.com/?id=2678.

Here is a synopsis of all five stocks:

Bull of the Day:

I remember when Evian launched their ad campaigns here in the US in 80s,
selling water for what then seemed like astronomical prices.

In the United States, a liter of bottled water can cost up to $3 per bottle,
while a similar volume of tap water costs less than one cent. According to a
NRDC study over 12 years ago, U.S. consumers paid between 240 and 10,000 times
more per unit volume for bottled water than for tap water.

To make things even more complicated, bottled water and tap water are
regulated by different federal agencies: the Food and Drug Administration
(FDA) regulates bottled water and the Environmental Protection Agency (EPA)
oversees the quality of tap water.

Several studies have found that the enforcement and monitoring of water
quality is irregular and inconsistent for both tap water and bottled water.
But contrary to popular belief, Tap water contamination incidents must be
reported promptly to the public, while the same is not true for bottled water.

A tap water renaissance would be wonderful for today's Bull of the Day, but
more realistic are the improvements to American water infrastructure. It's a
trend that's both needed and demanded by the people.

Water is essential to our daily lives and not everyone can afford to stock
bottled water or install a reverse osmosis system. Many of us also enjoy
taking showers in clean water…

Water, water everywhere…

…but getting it to where it's needed can be a problem.

The truth is that Mueller & Co (NYSE:MWA) is not the company that is filtering
your water for drinking or capitalizing on a shift from bottles back to the
tap. Mueller is one of the largest manufacturers of fire hydrants, butterfly
valves and iron gate valves in the U.S. and Canada and offers the broadest
product line of valves for residential water and gas systems.

Bear of the Day:

Cirrus Logic, Inc. (Nasdaq:CRUS), which supplies many of Apple's iDevices.
Between April 16 and April 18 of this year, the stock tanked by more than 17%,
and it lost about 20% on May 23.

Why? Well, about 90% of its revenue is tied to Apple Inc., and Apple's
position in the stock market today isn't what it used to be with Steve Jobs
gone, growth slowing, and margins being pressured.

In mid-April, Cirrus warned of disappointing upcoming results, and got
punished for it. In May, management cited profit-margin pressures of its own,
along with competition and a maturing smartphone environment.

Latest Posts on the Zacks Analyst Blog:

Nektar Presents Data on Oncology Candidates

Nektar Therapeutics (Nasdaq:NKTR) recently presented encouraging preclinical
data on NKTR-214 at the 2013 annual meeting of the American Society of
Clinical Oncology (ASCO). Nektar is developing NKTR-214 (targets the IL-2
receptor complex) as a potential treatment for multiple forms of cancer.

The preclinical data revealed that NKTR-214 was more effective and exhibited
greater tolerability compared to Novartis (NYSE:NVS)/Prometheus Laboratories'
Proleukin (aldesleukin). The company mentioned in its press release that
NKTR-214 was more effective compared to Proleukin in spite of being dosed with
20-fold less in total cytokine or being dosed only once every fourteen days.
NKTR-214 is also under development in other pre-clinical toxicological and
efficacy studies.

Nektar also presented a series of target-specific biomarkers that were being
developed in a phase III study on its etirinotecan pegol for the treatment of
breast cancer at the ASCO annual meeting. The randomized, open-label,
international BEACON (BrEAst Cancer Outcomes with NKTR-102) phase III study is
evaluating etirinotecan pegol in patients who have received an anthracycline,
a taxane and capecitabine (ATC) in comparison to a comparator arm which
consists of an active single agent treatment of physician's choice.

Nektar stated in its press release that multiple assays for target-specific
pharmacodynamic biomarkers for etirinotecan pegol have been established. They
are being measured under the BEACON study. These biomarkers were identified
from Circulating Tumor Cell (CTC) samples, which were collected before patient
treatment, during treatment (at regular intervals) and also at the end of
treatment.

The primary objective of the BEACON study is overall survival. The study will
also evaluate progression-free survival and objective tumor response rates of
etirinotecan pegol.

Nektar, a biopharmaceutical company, presently carries a Zacks Rank #3 (Hold).
Other biopharma stocks such as Cubist Pharmaceuticals Inc. (Nasdaq:CBST)
currently look better positioned. Cubist Pharma carries a Zacks Rank #2 (Buy).

Get the full analysis of all these stocks by going to
http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting http://at.zacks.com/?id=7158.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.